Cargando…
Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience
The adoption of neoadjuvant chemotherapy (NACT) for breast cancer (BC) is increasing. The need to repeat the biomarkers on a residual tumor after NACT is still a matter of debate. We verified estrogen receptors (ER), progesterone receptors (PR), Ki67 and human epidermal growth factor receptor 2 (HER...
Autores principales: | Coiro, Saverio, Gasparini, Elisa, Falco, Giuseppe, Santandrea, Giacomo, Foroni, Moira, Besutti, Giulia, Iotti, Valentina, Di Cicilia, Roberto, Foroni, Monica, Mele, Simone, Ferrari, Guglielmo, Bisagni, Giancarlo, Ragazzi, Moira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700750/ https://www.ncbi.nlm.nih.gov/pubmed/34943486 http://dx.doi.org/10.3390/diagnostics11122249 |
Ejemplares similares
-
Accuracy and Reproducibility of Contrast-Enhanced Mammography in the Assessment of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients with Calcifications in the Tumor Bed
por: Iotti, Valentina, et al.
Publicado: (2021) -
Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging
por: Iotti, Valentina, et al.
Publicado: (2017) -
Colonic metastasis from breast carcinoma detection by CESM and PET/CT: A case report
por: Falco, Giuseppe, et al.
Publicado: (2018) -
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2023) -
The network of commodity risk
por: Foroni, Beatrice, et al.
Publicado: (2022)